Janux Therapeutics, Inc. Operating Cash Flow
Janux Therapeutics, Inc. (JANX) reported Operating Cash Flow of $147.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-06
- Janux Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was $12.48M.
- Janux Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$12.34M.
- Janux Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$28.54M.
- Janux Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$12.86M.
- Janux Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$82.23M.
- Janux Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$43.81M.
- Janux Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$50.58M.
- Janux Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$42.92M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $12.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $147.00K 10-Q · filed 2026-08-06 | -$28.39M derived: sum of 3 quarters · filed 2026-08-06 | -$41.25M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$12.34M 10-Q · filed 2026-05-07 | -$40.88M derived: sum of 2 quarters · filed 2026-05-07 | -$53.73M derived: sum of 3 quarters · filed 2026-05-07 | -$77.55M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$28.54M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$41.40M derived: sum of 2 quarters · filed 2026-02-26 | -$65.21M derived: sum of 3 quarters · filed 2026-08-06 | -$82.23M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$12.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$36.67M derived: sum of 2 quarters · filed 2026-08-06 | -$53.69M 10-Q · filed 2025-11-06 | -$70.42M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$23.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$40.84M 10-Q · filed 2026-08-06 | -$57.56M derived: sum of 3 quarters · filed 2026-08-06 | -$59.79M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$17.02M 10-Q · filed 2026-05-07 | -$33.75M derived: sum of 2 quarters · filed 2026-05-07 | -$35.98M derived: sum of 3 quarters · filed 2026-05-07 | -$46.00M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$16.73M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$18.96M derived: sum of 2 quarters · filed 2026-02-26 | -$28.98M derived: sum of 3 quarters · filed 2026-02-26 | -$43.81M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$2.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$12.25M derived: sum of 2 quarters · filed 2025-11-06 | -$27.09M 10-Q · filed 2025-11-06 | -$36.99M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | -$10.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$24.86M 10-Q · filed 2025-08-07 | -$34.76M derived: sum of 3 quarters · filed 2026-02-26 | -$46.47M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$14.84M 10-Q · filed 2025-05-08 | -$24.74M derived: sum of 2 quarters · filed 2026-02-26 | -$36.45M derived: sum of 3 quarters · filed 2026-02-26 | -$51.50M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | -$9.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$21.61M derived: sum of 2 quarters · filed 2026-02-26 | -$36.66M derived: sum of 3 quarters · filed 2026-02-26 | -$50.58M 10-K · filed 2026-02-26 |
| 2023-09-30 | -$11.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$26.76M derived: sum of 2 quarters · filed 2024-11-06 | -$40.67M 10-Q · filed 2024-11-06 | -$52.59M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | -$15.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | -$28.96M 10-Q · filed 2024-08-07 | -$40.88M derived: sum of 3 quarters · filed 2025-02-27 | -$54.29M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | -$13.91M 10-Q · filed 2024-05-08 | -$25.82M derived: sum of 2 quarters · filed 2025-02-27 | -$39.24M derived: sum of 3 quarters · filed 2025-02-27 | -$45.31M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | -$11.91M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$25.33M derived: sum of 2 quarters · filed 2025-02-27 | -$31.40M derived: sum of 3 quarters · filed 2025-02-27 | -$42.92M 10-K · filed 2025-02-27 |
| 2022-09-30 | -$13.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$19.49M derived: sum of 2 quarters · filed 2023-11-07 | -$31.01M 10-Q · filed 2023-11-07 | -$41.49M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | -$6.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$17.59M 10-Q · filed 2023-08-08 | -$28.08M derived: sum of 3 quarters · filed 2023-08-08 | -$33.93M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | -$11.52M 10-Q · filed 2023-05-09 | -$22.00M derived: sum of 2 quarters · filed 2023-05-09 | -$27.86M derived: sum of 3 quarters · filed 2023-05-09 | -$34.06M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | -$10.48M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-10 | -$16.34M derived: sum of 2 quarters · filed 2023-03-10 | -$22.54M derived: sum of 3 quarters · filed 2023-03-10 | -$16.98M 10-K · filed 2023-03-10 |
| 2021-09-30 | -$5.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$12.06M derived: sum of 2 quarters · filed 2022-11-10 | -$6.50M 10-Q · filed 2022-11-10 | -$8.12M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$6.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$641.00K 10-Q · filed 2022-08-09 | -$2.27M derived: sum of 3 quarters · filed 2022-08-09 | -$3.35M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $5.56M 10-Q · filed 2022-05-10 | $3.93M derived: sum of 2 quarters · filed 2022-05-10 | $2.85M derived: sum of 3 quarters · filed 2022-05-10 | |
| 2020-12-31 | -$1.63M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-18 | -$2.71M derived: sum of 2 quarters · filed 2022-03-18 | -$4.37M 10-K · filed 2022-03-18 | |
| 2020-09-30 | -$1.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | -$2.74M 10-Q · filed 2021-11-09 | ||
| 2020-06-30 | -$1.66M 10-Q · filed 2021-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |